

The Sweetest Polymer Nanoparticles: Opportunities Ahead for Glycogen in Nanomedicine

Nadiia Davydiuk¹, Jiayi Liu¹, Vaidehi Londhe¹, Quinn A. Besford^{1 2}

¹Leibniz-Institut für Polymerforschung Dresden e.V., Hohe Str. 6, Dresden 01069, Germany

²Faculty of Chemistry and Food Chemistry, Technische Universität Dresden, Dresden 01069, Germany

besford@ipfdd.de

There is a compelling need for non-toxic and biodegradable nanomaterials in healthcare and medicine, where innovations in the bioengineering of first-generation nanoparticles have primarily focused on synthetic non-degradable polymers, which can have undesirable interactions with our immune system in human blood [1]. In our work, we look to leverage biology against itself in nanomedicine, done so through the use of biomaterial glycogen nanoparticles. Glycogen is a unique biological polysaccharide nanoparticle fabricated by nature through a bottom-up approach [2], which is markedly different from other natural biomaterials. Glycogen is inherently biodegradable, nontoxic, and can be functionalised with diverse surface and internal motifs for enhanced biofunctional properties. [3] In our work, we show how to functionalise glycogen nanoparticles for a therapeutic purpose, before re-integrating them back into biological contexts. These particles have been devised for targeting cancer cells [4], delivering siRNA in tumour spheroids [5], and as highly adhesive biomaterial films [6]. We have proved these nanoparticles to be essentially invisible to our immune system in human blood [7], which leads for them to be used as in-blood active nanoparticles for treating thrombosis and as fibrinolytic (blood clot-busting) agents [8]. Together, our work shows how sugary glycogen nanoparticles can be nano-engineered for functional therapeutic purposes, taken from nature, and reintegrated into biology with a new purpose.

Keywords:

Glycogen, Nanomedicine, Hemocompatibility, Blood Interactions, Colloidal Nanoparticles

References:

[1] Vaidehi Londhe, Manfred F. Maitz, Triantafyllos Chavakis, Carsten Werner, Alessia C.G. Weiss, Quinn A. Besford, *Advanced Healthcare Materials* **2025**, *14*, 2501431. [2] Quinn A. Besford, Francesca Cavalieri, Frank Caruso, *Advanced Materials* **2020**, *32*, 1904625. [3] Quinn A. Besford, *Soft Matter* **2024**, *20*, 3577-3584. [4] Quinn A. Besford, Marcin Wojnilowicz, Tomoya Suma, Nadja Bertleff-Zieschang, Frank Caruso, Francesca Cavalieri, *ACS Applied Materials & Interfaces* **2017**, *9*, 16869-16879. [5] Marcin Wojnilowicz, Quinn A. Besford, Yun-Long Wu, Xian J. Loh, Julia A. Braunger, Agata Glab, Christina Cortez-Jugo, Frank Caruso, Francesca Cavalieri, *Biomaterials* **2018**, *176*, 34-49. [6] Jiayi Liu, Dmitrii Sychev, Nadiia Davydiuk, Mahmoud Al-Hussein, Andreas Fery, Quinn A. Besford, *Soft Matter* **2025**, *21*, 2282-2290. [7] Nadiia Davydiuk, Vaidehi Londhe, Manfred F. Maitz, Carsten Werner, Andreas Fery, Quinn A. Besford, *Nanoscale* **2025**, *17*, 252-260. [8] Nadiia Davydiuk, Vaidehi Londhe, Susanne Boye, Martin Müller, Carsten Werner, Manfred F. Maitz, Quinn A. Besford, *Under Revision* **2026**.